Skip to main content
. 2015 Dec 2;127(6):713–721. doi: 10.1182/blood-2015-09-665018

Figure 1.

Figure 1

PFS based on prior treatment. Kaplan-Meier analysis of PFS for each prior treatment subgroup. (A) Kaplan-Meier analysis of PFS among patients who received prior treatment with an IMiD. (B) Kaplan-Meier analysis of PFS among patients who received prior treatment with bortezomib and an IMiD. (C) PFS among patients who received ≥2 prior regimens including bortezomib and an IMiD.